Evidence map›Paper›PMID 28569347›Full record

ArticleInvestigational new drugs2017

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.

Valentine Heidelberger, François Goldwasser, Nora Kramkimel, Anne Jouinot, Nathalie Franck, Jennifer Arrondeau, Sarah Guégan, Audrey Mansuet-Lupo, Jérôme Alexandre, Diane Damotte and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Valentine HeidelbergerDepartment of Medical Oncology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
François GoldwasserDepartment of Medical Oncology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France. francois.goldwasser@aphp.fr.
Nora KramkimelDepartment of Dermatology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Anne JouinotDepartment of Medical Oncology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Nathalie FranckDepartment of Dermatology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Jennifer ArrondeauDepartment of Medical Oncology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Sarah GuéganDepartment of Dermatology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Audrey Mansuet-LupoDepartment of Pathology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 27, rue du Faubourg Saint Jacques, F75014, Paris, France.
Jérôme AlexandreDepartment of Medical Oncology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Diane DamotteDepartment of Pathology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 27, rue du Faubourg Saint Jacques, F75014, Paris, France.
Marie-Françoise AvrilDepartment of Dermatology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Nicolas DupinDepartment of Dermatology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Sélim AractingiDepartment of Dermatology, Teaching Hospital Cochin, AP-HP, University Paris Descartes, 123 Bd Port Royal, 75 679, Paris Cedex 14, France.
Assistance Publique – Hôpitaux de Paris · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The identification of the melanoma patients sensitive to anti-PD-1 inhibitors, nivolumab or pembrolizumab, is a major therapeutic challenge and an urgent need. We hypothesized that the natural history of the disease might partly reflect the immune state of the patients. Methods We analyzed our cohort of melanoma patients treated with anti-PD-1 from August 2014 to January 2016 in our institution. Objective response was defined as a complete or partial response according to v1.1 RECIST criteria. Results Among 63 metastatic melanoma patients, the overall response rate was 43%. Median time from diagnosis to anti-PD-1 initiation was longer among responders than non-responders (64 months vs. 35 months, p = 0.02). The response rate was 10% in patients starting anti-PD-1 within 1 year, 35% after 1 to 5 years and 63% after 5 years. Performance status (PS) 0 was also associated with enhanced tumor response: 70% of responders were PS 0 vs. 36% of non-responders (p = 0.04). PS 0, normal LDH levels and wild-type BRAF status were significant predictors of progression free survival. Conclusion A long time lapse from diagnosis to anti-PD-1 initiation and PS 0 are associated with higher sensitivity to anti-PD-1 in melanoma patients. These two clinical features might reflect a potentially intact immune system of the host.

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMelanomaMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedNivolumabPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorDisease kineticsDisseminationMelanomaNivolumabPembrolizumabPrognostic factors

Identifiers

PMID28569347
OpenAlexW2617468510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.